文献速递肾移植

肾移植受者转换为贝拉西普免疫抑制方案的长期结局

Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-02-22

该前瞻性匹配研究纳入311例肾移植受者,将243例转换为贝拉西普方案者与243例维持钙调神经磷酸酶抑制剂(CNI)者匹配,随访7年发现贝拉西普组移植物存活率78%高于CNI组63%(P<0.001),安全结局总体可接受,但新发蛋白尿率更高(37% vs 21%,P<0.001)。

要点

  • 转换至贝拉西普与7年移植物存活率改善相关(78% vs 63%)
  • 患者死亡、排斥反应、心血管事件及肿瘤发生率与CNI组相似
  • 贝拉西普组新发蛋白尿发生率显著更高(37% vs 21%)

核心结论

  • 真实世界证据显示肾移植后转换为贝拉西普与较低的移植物衰竭风险相关,安全结局可接受。

研究设计与样本

  • 前瞻性纳入2007至2020年两家转诊中心的311例肾移植受者,按预设方案从CNI转换为贝拉西普。
  • 采用最优匹配法将243例转换者与243例维持CNI者按转换时点匹配,标准化均数差均低于0.05。
  • 主要终点为7年死亡删失的移植物存活率,次要终点包括患者生存、eGFR及安全性结局。

主要发现

  • 转换至贝拉西普后7年移植物存活率为78%,CNI对照组为63%(P<0.001,log-rank检验)。
  • 患者死亡率贝拉西普组28%、CNI组36%;活动性抗体介导排斥6% vs 7%;T细胞介导排斥4% vs 4%。
  • 主要不良心血管事件与肿瘤发生率两组相似,肿瘤发生率为9% vs 11%。
  • 贝拉西普组新发蛋白尿发生率显著高于CNI组(37% vs 21%,P<0.001)。

关键数值与推荐

  • 转换至贝拉西普者7年移植物存活率78%,维持CNI者63%(P<0.001)。
  • 新发蛋白尿发生率贝拉西普组37%、CNI组21%(P<0.001)。

临床怎么用

  • 对CNI不耐受的肾移植受者,转换为贝拉西普可作为CNI回避策略,可能改善长期移植物存活。
  • 转换后需监测新发蛋白尿,该组发生率显著高于维持CNI者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conversion to a belatacept-based immunosuppression is currently used as a calcineurin inhibitor (CNI) avoidance strategy when the CNI-based standard-of-care immunosuppression is not tolerated after kidney transplantation. However, there is a lack of evidence on the long-term benefit and safety after conversion to belatacept. METHODS: We prospectively enrolled 311 kidney transplant recipients from 2007 to 2020 from two referral centers, converted from CNI to belatacept after transplant according to a prespecified protocol. Patients were matched at the time of conversion to patients maintained with CNIs, using optimal matching. The primary end point was death-censored allograft survival at 7 years. The secondary end points were patient survival, eGFR, and safety outcomes, including serious viral infections, immune-related complications, antibody-mediated rejection, T-cell-mediated rejection, de novo anti-HLA donor-specific antibody, de novo diabetes, cardiovascular events, and oncologic complications. RESULTS: A total of 243 patients converted to belatacept (belatacept group) were matched to 243 patients maintained on CNIs (CNI control group). All recipient, transplant, functional, histologic, and immunologic parameters were well balanced between the two groups with a standardized mean difference below 0.05. At 7 years post-conversion to belatacept, allograft survival was 78% compared with 63% in the CNI control group ( P < 0.001 for log-rank test). The safety outcomes showed a similar rate of patient death (28% in the belatacept group versus 36% in the CNI control group), active antibody-mediated rejection (6% versus 7%), T-cell-mediated rejection (4% versus 4%), major adverse cardiovascular events, and cancer occurrence (9% versus 11%). A significantly higher rate of de novo proteinuria was observed in the belatacept group as compared with the CNI control group (37% versus 21%, P < 0.001). CONCLUSIONS: This real-world evidence study shows that conversion to belatacept post-transplant was associated with lower risk of graft failure and acceptable safety outcomes compared with patients maintained on CNIs. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Long-term Outcomes after Conversion to Belatacept, NCT04733131 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Divard G, Aubert O, Debiais-Deschamp C, et al. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2024. PMID: 38265815. doi:10.2215/CJN.0000000000000411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。